Sign in

NCT04599478CompletedPhase 2/3

Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)

Pharmacological and Behavioral Treatments to Treat Loss-of-Control Eating and Improve Weight Outcomes After Bariatric Surgery: Acute (Stage 1)

Source: ClinicalTrials.gov · Last updated 26 Aug 2026

Brief summary (registry, in English)

This study will compare the effectiveness of behavioral and pharmacologic treatments, alone and in combination, for the treatment of loss-of-control eating and weight following bariatric surgery. This is an acute treatment comparing behavioral weight loss alone or in combination with combination naltrexone/bupropion medication.

Status (registry)
Completed
Phase (registry)
Phase 2/3
Study type
Interventional
Enrollment
92 (actual)
First submitted
21 Oct 2020
Start date
29 Jun 2021
Primary completion date
4 Jun 2026
Lead sponsor
Yale University
Diseases
Obesity
NCT number
NCT04599478

What you commit to

  • Study type: Interventional · Phase 2/3
  • Participants enrolled: 92
  • From 29 Jun 2021 to the primary completion date, 4 Jun 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).
  • Is currently taking a medication that is a contraindication to NB medication (e.g., MAOI, opiates).
  • Is currently using other medications for weight loss.
  • Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.

Other illness

  • Has a history of anorexia nervosa or history of bulimia nervosa.
  • Has a history of allergy or sensitivity to bupropion or naltrexone.
  • Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)
  • Has untreated hypertension with a seated systolic blood pressure \> 160 mmHg, diastolic blood pressure \> 100 mmHg, or heart rate \> 100 beats/minute.
  • Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.
  • Has current uncontrolled hypertension.
  • Has current uncontrolled Type I or Type II diabetes mellitus.
  • Has gallbladder disease.
  • Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder.
  • Has a recent history of drug or alcohol dependence (since having bariatric surgery).

Lab values

  • Has untreated hypothyroidism with a TSH \> 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit.

Other

  • Is currently in active treatment for eating or weight loss.
  • Is breast-feeding or is pregnant or is not using a reliable form of birth control.
  • Reports active suicidal or homicidal ideation.

Who the study is looking for

  • Be in the age range ≥18 years of age and ≤70 years of age.
  • Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and ≤50
  • Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy
  • Approximately six months post-surgery
  • Experience regular loss-of-control eating (defined as at least once weekly over the past 28 days)
  • Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators (physical examination, laboratory studies).
  • Read, comprehend, and write English at a sufficient level to complete study-related materials.
  • Provide a signed and dated written informed consent prior to study participation.
    • Be available for participation in the study for up to 19 months (7-month treatment plus 12-month follow up).

Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Yale Department of Psychiatry
Coordinator of this site? Confirm its status
New HavenUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.